Blood MxA protein as a marker for respiratory virus infections in young children

Journal of Clinical Virology

Volumn 62, Issue , 2015, Pages 8-13

  Toivonen, Laura ^a,b   Schuez Havupalo, Linnea ^a,b   Rulli, Maris ^a,b   Ilonen, Jorma ^b,c   Pelkonen, Jukka ^c   Melen, Krister ^d   Julkunen, Ilkka ^b,d   Peltola, Ville ^a,b   Waris, Matti ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Interferon; MxA protein; Respiratory virus infection; Rhinovirus; Rotavirus vaccine; STEPS study

Indexed keywords

BIOLOGICAL MARKER; LIVE VACCINE; MYXOVIRUS RESISTANCE PROTEIN A; ROTAVIRUS VACCINE; C REACTIVE PROTEIN; MX1 PROTEIN, HUMAN; MYXOVIRUS RESISTANCE PROTEIN;

ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CHILD; CORONAVIRUS; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN METAPNEUMOVIRUS INFECTION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA VIRUS; MAJOR CLINICAL STUDY; MALE; NOSE SMEAR; PARAINFLUENZA VIRUS; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; RESPIRATORY VIRUS; RHINOVIRUS; RHINOVIRUS INFECTION; VACCINATION; VIRAL RESPIRATORY TRACT INFECTION; BLOOD; INFANT; LEUKOCYTE COUNT; PROSPECTIVE STUDY; RESPIRATORY TRACT INFECTIONS; VIROLOGY;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFANT; LEUKOCYTE COUNT; MALE; MYXOVIRUS RESISTANCE PROTEINS; PROSPECTIVE STUDIES; RESPIRATORY TRACT INFECTIONS;

EID: 84920467004     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2014.11.018     Document Type: Article

References (31)

1. Tregoning J.S., Schwarze J. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin Microbiol Rev 2010, 23:74-98.
2. von Wussow P., Jakschies D., Hochkeppel H.K., Fibich C., Penner L., Deicher H. The human intracellular Mx-homologous protein is specifically induced by type I interferons. Eur J Immunol 1990, 20:2015-2019.
3. Simon A., Fäh J., Haller O., Staeheli P. Interferon-regulated Mx genes are not responsive to interleukin-1, tumor necrosis factor, and other cytokines. J Virol 1991, 65:968-971.
4. Ronni T., Matikainen S., Lehtonen A., Palvimo J., Dellis J., Van Eylen F., et al. The proximal interferon-stimulated response elements are essential for interferon responsiveness: a promoter analysis of the antiviral MxA gene. J Interferon Cytokine Res 1998, 18:773-781.
5. Kotenko S.V., Gallagher G., Baurin V.V., Lewis-Antes A., Shen M., Shah N.K., et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003, 4:69-77.
6. Holzinger D., Jorns C., Stertz S., Boisson-Dupuis S., Thimme R., Weidmann M., et al. Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol 2007, 81:7776-7785.
7. Haller O., Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J Interferon Cytokine Res 2011, 31:79-87.
8. Ronni T., Melén K., Malygin A., Julkunen I. Control of IFN-inducible MxA gene expression in human cells. J Immunol 1993, 150:1715-1726.
9. Maria N.I., Brkic Z., Waris M., van Helden-Meeuwsen C.G., Heezen K., van de Merwe J.P., et al. MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndrome. Ann Rheum Dis 2014, 73:1052-1059.
10. Roers A., Hochkeppel H.K., Horisberger M.A., Hovanessian A., Haller O. MxA gene expression after live virus vaccination: a sensitive marker for endogenous type I interferon. J Infect Dis 1994, 169:807-813.
11. Halminen M., Ilonen J., Julkunen I., Ruuskanen O., Simell O., Mäkelä M.J. Expression of MxA protein in blood lymphocytes discriminates between viral and bacterial infections in febrile children. Pediatr Res 1997, 41:647-650.
12. Mäkelä M.J., Halminen M., Ruuskanen O., Puhakka T., Pirhonen J., Julkunen I., et al. Lack of induction by rhinoviruses of systemic type I interferon production or enhanced MxA protein expression during the common cold. Eur J Clin Microbiol Infect Dis 1999, 18:665-668.
13. Selvaggi C., Pierangeli A., Fabiani M., Spano L., Nicolai A., Papoff P., et al. Interferon lambda 1-3 expression in infants hospitalized for RSV or HRV associated bronchiolitis. J Infect 2014, 68:467-477.
14. Mäkelä M.J., Puhakka T., Ruuskanen O., Leinonen M., Saikku P., Kimpimäki M., et al. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol 1998, 36:539-542.
15. Miller E.K., Lu X., Erdman D.D., Poehling K.A., Zhu Y., Griffin M.R., et al. Rhinovirus-associated hospitalizations in young children. J Infect Dis 2007, 195:773-781.
16. Mackay I.M., Lambert S.B., Faux C.E., Arden K.E., Nissen M.D., Sloots T.P., et al. Community-wide, contemporaneous circulation of a broad spectrum of human rhinoviruses in healthy Australian preschool-aged children during a 12-month period. J Infect Dis 2013, 207:1433-1441.
17. Lagström H., Rautava P., Kaljonen A., Räihä H., Pihlaja P., Korpilahti P., et al. Cohort profile: Steps to the healthy development and well-being of children (the STEPS Study). Int J Epidemiol 2013, 42:1273-1284.
18. Peltola V., Waris M., Osterback R., Susi P., Ruuskanen O., Hyypia T. Rhinovirus transmission within families with children: incidence of symptomatic and asymptomatic infections. J Infect Dis 2008, 197:382-389.
19. Waris M., Osterback R., Lahti E., Vuorinen T., Ruuskanen O., Peltola V. Comparison of sampling methods for the detection of human rhinovirus RNA. J Clin Virol 2013, 58:200-204.
20. Vallittu A.M., Erälinna J.P., Ilonen J., Salmi A.A., Waris M. MxA protein assay for optimal monitoring of IFN-beta bioactivity in the treatment of MS patients. Acta Neurol Scand 2008, 118:12-17.
21. Bellingan G., Maksimow M., Howell D.C., Stotz M., Beale R., Beatty M., et al. The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. Lancet Respir Med 2014, 2:98-107.
22. Ruuskanen O., Waris M., Kainulainen L. Treatment of persistent rhinovirus infection with pegylated interferon alpha 2a and ribavirin in patients with hypogammaglobulinemia. Clin Infect Dis 2014, 58:1784-1786.
23. Osterback R., Tevaluoto T., Ylinen T., Peltola V., Susi P P., Hyypiä T., et al. Simultaneous detection and differentiation of human rhino- and enteroviruses in clinical specimens by real-time PCR with locked nucleic Acid probes. J Clin Microbiol 2013, 51:3960-3967.
24. Koskenvuo M., Möttönen M., Waris M., Allander T., Salmi T.T., Ruuskanen O. Human bocavirus in children with acute lymphoblastic leukemia. Eur J Pediatr 2008, 167:1011-1015.
25. Forster J., Schweizer M., Schumacher R.F., Kaufmehl K., Lob S. MxA protein in infants and children with respiratory tract infection. Acta Paediatr 1996, 85:163-167.
26. Chieux V., Hober D., Chehadeh W., Harvey J., Alm G., Cousin J., et al. MxA protein in capillary blood of children with viral infections. J Med Virol 1999, 59:547-551.
27. Nakabayashi M., Adachi Y., Itazawa T., Okabe Y., Kanegane H., Kawamura M., et al. MxA-based recognition of viral illness in febrile children by a whole blood assay. Pediatr Res 2006, 60:770-774.
28. Bartlett N.W., Slater L., Glanville N., et al. Defining critical roles for NF-(B p65 and type I interferon in innate immunity to rhinovirus. EMBO Mol Med 2012, 4:1244-1260.
29. Jartti T., Jartti L., Peltola V., Waris M., Ruuskanen O. Identification of respiratory viruses in asymptomatic subjects: asymptomatic respiratory viral infections. Pediatr Infect Dis J 2008, 27:1103-1107.
30. Chorazy M.L., Lebeck M.G., McCarthy T.A., Richter S.S., Torner J.C., Gray G.C. Polymicrobial acute respiratory infections in a hospital-based pediatric population. Pediatr Infect Dis J 2013, 32:460-466.
31. Jansen R.R., Wieringa J., Koekkoek S.M., Visser C.E., Pajkrt D., Molenkamp R., et al. Frequent detection of respiratory viruses without symptoms: toward defining clinically relevant cutoff values. J Clin Microbiol 2011, 49:2631-2636.